NONOF - Senate panel to consider subpoenas for J&J and Merck CEOs
2024-01-19 08:05:15 ET
More on Bristol-Myers, J&J, etc.
- Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?
- Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition
- Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal
- Eli Lilly’s Jaypirca to lead BTK inhibitor market for leukemia
- Adagene falls after trial data for cancer therapy
For further details see:
Senate panel to consider subpoenas for J&J and Merck CEOs